IDEXX Laboratories (XTER:IX1) Moat Score: 8/10 (As of Jun. 25, 2026)


XTER:IX1 IDEXX Laboratories Inc XTER:IX1
96 GF Score
Price €488.90
GF Value €561.51
View Full Analysis

What is IDEXX Laboratories Moat Score?

IDEXX Laboratories XTER:IX1 96 Moat Score is 8 as of Jun. 25, 2026. GuruFocus rates XTER:IX1 with a GF Score™ of 96/100 and a GF Value™ of €561.51. Among 217 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 99.08% on this metric.

IDEXX Laboratories has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

IDEXX Laboratories has Wide Moat: IDEXX Laboratories Inc possesses a clear and robust wide moat due to its strong brand, significant customer loyalty, and valuable intellectual property. It leads the veterinary diagnostics market with durable cost advantages and consistent innovation.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes IDEXX Laboratories might have Wide Moat - Clear and robust wide moat.

IDEXX Laboratories  (XTER:IX1) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

IDEXX Laboratories Moat Score Related Terms

XTER:IX1 vs A, WAT, NTRA: Moat Score Comparison

For the Diagnostics & Research subindustry, IDEXX Laboratories's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDEXX Laboratories Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Moat Score distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's Moat Score falls into.


XTER:IX1
96GF Score
IDEXX Laboratories Inc XTER:IX1
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 8 mean?
IDEXX Laboratories (XTER:IX1) has a Moat Score of 8 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, IDEXX Laboratories ranks #2 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 0.90000000000001%.
Is IDEXX Laboratories' Moat Score too high?
IDEXX Laboratories' current Moat Score is 8. Based on the distribution chart, IDEXX Laboratories ranks #2 out of 217 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Moat Score compare to A and WAT?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #2 out of 217 companies for Moat Score. This places IDEXX Laboratories in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. IDEXX Laboratories's current Moat Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
IDEXX Laboratories (XTER:IX1) has a current Moat Score of 8. The stock's GF Value™ is €561.51, compared to a current price of €488.90 — trading 12.9% below its estimated fair value. The current Moat Score is 8. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For IDEXX Laboratories (XTER:IX1), the current Moat Score is 8 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (XTER:IX1) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of €488.90 is trading 12.9% below its estimated GF Value™ of €561.51.

Key valuation signals for XTER:IX1:

  • Moat Score: 8
  • GF Value™: €561.51 vs. price of €488.90 (12.9% below fair value)
  • GF Score™: 96/100

No single metric tells the full story. See the XTER:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score

Get the complete analysis for XTER:IX1

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€488.90
Price
€561.51
GF Value